Evaluating the use of lamotrigine to reduce mood lability and impulsive behaviors in adults with chronic and severe eating disorders.
Anorexia nervosa
Bulimia nervosa
Emotion dysregulation
Impulsivity
Lamotrigine
Journal
Eating and weight disorders : EWD
ISSN: 1590-1262
Titre abrégé: Eat Weight Disord
Pays: Germany
ID NLM: 9707113
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
23
08
2021
accepted:
13
10
2021
pubmed:
18
3
2022
medline:
25
5
2022
entrez:
17
3
2022
Statut:
ppublish
Résumé
Gold-standard psychological and pharmacological treatments for bulimic-spectrum eating disorders only result in remission for around 50% of patients; patients with affective lability and impulsivity represent a subgroup with particularly poor outcomes. Both dialectical behavior therapy (DBT), a treatment for emotion dysregulation, and lamotrigine, a mood stabilizer, have demonstrated promise for targeting affective lability and impulsivity; however, data exploring the combination of these interventions remain limited. We followed a group of women with recurrent dysregulated eating behaviors (N = 62) throughout intensive DBT treatment and compared the symptom trajectory of those prescribed lamotrigine (n = 28) and those who were not (n = 34). Participants completed surveys every 2 weeks throughout treatment. Group analyses suggested that all participants self-reported decreases in emotional reactivity, negative urgency, and symptoms of borderline personality disorder (BPD). The lamotrigine group reported greater elevations in BPD symptoms at baseline, but demonstrated steeper decreases in emotion and behavioral dysregulation than the non-matched comparison group. Within-subject analyses suggested that within the lamotrigine group, subjects reported greater decreases in symptoms following prescription of lamotrigine. Findings provide initial data suggesting that lamotrigine could be useful as an adjunctive treatment for patients with affective lability and impulsivity. IV, time series without randomization.
Sections du résumé
BACKGROUND
BACKGROUND
Gold-standard psychological and pharmacological treatments for bulimic-spectrum eating disorders only result in remission for around 50% of patients; patients with affective lability and impulsivity represent a subgroup with particularly poor outcomes. Both dialectical behavior therapy (DBT), a treatment for emotion dysregulation, and lamotrigine, a mood stabilizer, have demonstrated promise for targeting affective lability and impulsivity; however, data exploring the combination of these interventions remain limited.
OBJECTIVE
OBJECTIVE
We followed a group of women with recurrent dysregulated eating behaviors (N = 62) throughout intensive DBT treatment and compared the symptom trajectory of those prescribed lamotrigine (n = 28) and those who were not (n = 34).
METHOD
METHODS
Participants completed surveys every 2 weeks throughout treatment.
RESULTS
RESULTS
Group analyses suggested that all participants self-reported decreases in emotional reactivity, negative urgency, and symptoms of borderline personality disorder (BPD). The lamotrigine group reported greater elevations in BPD symptoms at baseline, but demonstrated steeper decreases in emotion and behavioral dysregulation than the non-matched comparison group. Within-subject analyses suggested that within the lamotrigine group, subjects reported greater decreases in symptoms following prescription of lamotrigine.
CONCLUSIONS
CONCLUSIONS
Findings provide initial data suggesting that lamotrigine could be useful as an adjunctive treatment for patients with affective lability and impulsivity.
LEVEL OF EVIDENCE
METHODS
IV, time series without randomization.
Identifiants
pubmed: 35298791
doi: 10.1007/s40519-021-01320-3
pii: 10.1007/s40519-021-01320-3
pmc: PMC9123051
mid: NIHMS1809080
doi:
Substances chimiques
Lamotrigine
U3H27498KS
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1775-1785Subventions
Organisme : NIMH NIH HHS
ID : F32 MH108311
Pays : United States
Organisme : NIMH NIH HHS
ID : K23 MH118418
Pays : United States
Organisme : NIMH NIH HHS
ID : K23MH118418
Pays : United States
Organisme : NIMH NIH HHS
ID : F32MH108311
Pays : United States
Organisme : NIMH NIH HHS
ID : F32MH108311
Pays : United States
Organisme : NIMH NIH HHS
ID : K23MH118418
Pays : United States
Informations de copyright
© 2022. The Author(s).
Références
Keel PK, Brown TA (2010) Update on course and outcome in eating disorders. Int J Eat Disord 43:195–204. https://doi.org/10.1002/eat.20810
doi: 10.1002/eat.20810
pubmed: 20186717
Fichter MM, Quadflieg N, Rief W (1994) Course of multi-impulsive bulimia. Psychol Med 24:591–604. https://doi.org/10.1017/s0033291700027744
doi: 10.1017/s0033291700027744
pubmed: 7991741
Corstorphine E, Waller G, Lawson R, Ganis C (2007) Trauma and multi-impulsivity in the eating disorders. Eat Behav 8:23–30. https://doi.org/10.1016/j.eatbeh.2004.08.009
doi: 10.1016/j.eatbeh.2004.08.009
pubmed: 17174848
Svirko E, Hawton K (2007) Self-injurious behavior and eating disorders: the extent and nature of the association. Suicide Life Threat Behav 37:409–421. https://doi.org/10.1521/suli.2007.37.4.409
doi: 10.1521/suli.2007.37.4.409
pubmed: 17896881
Agras WS, Crow SJ, Halmi KA, Mitchell JE, Wilson GT, Kraemer HC (2000) Outcome predictors for the cognitive behavior treatment of bulimia nervosa: data from a multisite study. Am J Psychiatry 157:1302–1308. https://doi.org/10.1176/appi.ajp.157.8.1302
doi: 10.1176/appi.ajp.157.8.1302
pubmed: 10910795
Favaro A, Santonastaso P (2000) Self-injurious behavior in anorexia nervosa. J Nerv Ment Dis 188:537–542. https://doi.org/10.1097/00005053-200008000-00010
doi: 10.1097/00005053-200008000-00010
pubmed: 10972574
Peake KJ, Limbert C, Whitehead L (2005) Gone, but not forgotten: an examination of the factors associated with dropping out from treatment of eating disorders. Eur Eat Disord Rev 13:330–337. https://doi.org/10.1002/erv.645
doi: 10.1002/erv.645
Helverskov JL, Clausen L, Mors O, Frydenberg M, Thomsen PH, Rokkedal K (2010) Trans-diagnostic outcome of eating disorders: a 30-month follow-up study of 629 patients. Eur Eat Disord Rev 18:453–463. https://doi.org/10.1002/erv.1025
doi: 10.1002/erv.1025
pubmed: 20593480
Rossiter EM, Agras WS, Telch CF, Schneider JA (1993) Cluster B personality disorder characteristics predict outcome in the treatment of bulimia nervosa. Int J Eat Disord 13:349–357. https://doi.org/10.1002/1098-108X(199305)13:4%3c349::AID-EAT2260130403%3e3.0.CO;2-C
doi: 10.1002/1098-108X(199305)13:4<349::AID-EAT2260130403>3.0.CO;2-C
pubmed: 8490637
Vall E, Wade TD (2015) Predictors of treatment outcome in individuals with eating disorders: a systematic review and meta-analysis. Int J Eat Disord 48:946–971. https://doi.org/10.1002/eat.22411
doi: 10.1002/eat.22411
pubmed: 26171853
Kliem S, Kröger C, Kosfelder J (2010) Dialectical behavior therapy for borderline personality disorder: a meta-analysis using mixed-effects modeling. J Consult Clin Psychol 78:936–951. https://doi.org/10.1037/a0021015
doi: 10.1037/a0021015
pubmed: 21114345
Linehan MM (2018) Cognitive-behavioral treatment of borderline personality disorder. Guilford Publications
Federici A, Wisniewski L, Ben-Porath D (2012) Description of an intensive dialectical behavior therapy program for multidiagnostic clients with eating disorders. J Couns Dev 90:330–338. https://doi.org/10.1002/j.1556-6676.2012.00041.x
doi: 10.1002/j.1556-6676.2012.00041.x
Wisniewski L, Kelly E (2003) The application of dialectical behavior therapy to the treatment of eating disorders. Cogn Behav Pract 10:131–138. https://doi.org/10.1016/S1077-7229(03)80021-4
doi: 10.1016/S1077-7229(03)80021-4
Coker S, Vize C, Wade T, Cooper PJ (1993) Patients with bulimia nervosa who fail to engage in cognitive behavior therapy. Int J Eat Disord 13:35–40. https://doi.org/10.1002/1098-108x(199301)13:1%3c35::aid-eat2260130105%3e3.0.co;2-n
doi: 10.1002/1098-108x(199301)13:1<35::aid-eat2260130105>3.0.co;2-n
pubmed: 8477275
Preston GA, Marchant BK, Reimherr FW, Strong RE, Hedges DW (2004) Borderline personality disorder in patients with bipolar disorder and response to lamotrigine. J Affect Disord 79:297–303. https://doi.org/10.1016/S0165-0327(02)00358-0
doi: 10.1016/S0165-0327(02)00358-0
pubmed: 15023511
Reich DB, Zanarini MC, Bieri KA (2009) A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int Clin Psychopharmacol 24:270–275. https://doi.org/10.1097/YIC.0b013e32832d6c2f
doi: 10.1097/YIC.0b013e32832d6c2f
pubmed: 19636254
Crawford MJ, Sanatinia R, Barrett B, Cunningham G, Dale O, Ganguli P, Lawrence-Smith G, Leeson VC, Lemonsky F, Lykomitrou-Matthews G, Montgomery A, Morriss R, Munjiza J, Paton C, Skorodzien I, Singh V, Tan W, Tyrer P, Reilly JG (2018) Lamotrigine for people with borderline personality disorder: a RCT. Health Technol Assess Winch Engl 22:1–68. https://doi.org/10.3310/hta22170
doi: 10.3310/hta22170
Trunko ME, Schwartz TA, Marzola E, Klein AS, Kaye WH (2014) Lamotrigine use in patients with binge eating and purging, significant affect dysregulation, and poor impulse control. Int J Eat Disord 47:329–334. https://doi.org/10.1002/eat.22234
doi: 10.1002/eat.22234
pubmed: 24343841
Trunko ME, Schwartz TA, Berner LA, Cusack A, Nakamura T, Bailer UF, Chen JY, Kaye WH (2017) A pilot open series of lamotrigine in DBT-treated eating disorders characterized by significant affective dysregulation and poor impulse control. Borderline Pers Disord Emot Dysregul 4:21. https://doi.org/10.1186/s40479-017-0072-6
doi: 10.1186/s40479-017-0072-6
Metropolitan Life Insurance Company (1957) New weight standards for men and women. Stat Bull 40:1–4
First M, Williams J, Karg R, Spitzer R (2015) Structured clinical interview for DSM-5—research version (SCID-5 for DSM-5, research version; SCID-5-RV). American Psychiatric Association, Arlington
Sheehan D, Lecrubier Y, Harnett Sheehan K, Janavs J, Weiller E, Keskiner A, Schinka J, Knapp E, Sheehan M, Dunbar G (1997) The validity of the Mini International Neuropsychiatric Interview (MINI) according to the SCID-P and its reliability. Eur Psychiatry 12:232–241. https://doi.org/10.1016/S0924-9338(97)83297-X
doi: 10.1016/S0924-9338(97)83297-X
Pfohl B, Blum N, St. John D, McCormick B, Allen J, Black DW (2009) Reliability and validity of the borderline evaluation of severity over time (BEST): a self-rated scale to measure severity and change in persons with borderline personality disorder. J Personal Disord 23:281–293. https://doi.org/10.1521/pedi.2009.23.3.281
doi: 10.1521/pedi.2009.23.3.281
Nock MK, Wedig MM, Holmberg EB, Hooley JM (2008) The emotion reactivity scale: development, evaluation, and relation to self-injurious thoughts and behaviors. Behav Ther 39:107–116. https://doi.org/10.1016/j.beth.2007.05.005
doi: 10.1016/j.beth.2007.05.005
pubmed: 18502244
Lynam DR, Smith GT, Whiteside SA, Cynders MA (2006) The UPPS-P: assessing five personality pathways to impulsive behavior. West Lafayette Purdue Univ 10
Fairburn CG (2008) Cognitive behavior therapy and eating disorders. Guilford Press
Bates D, Mächler M, Bolker B, Walker S (2015) Fitting linear mixed-effects models using lme4. J Stat Softw 67:1–48. https://doi.org/10.18637/jss.v067.i01
doi: 10.18637/jss.v067.i01
Schaumberg K, Reilly EE, Anderson LM, Gorrell S, Wang SB, Sala M (2018) Improving prediction of eating-related behavioral outcomes with zero-sensitive regression models. Appetite 129:252–261. https://doi.org/10.1016/j.appet.2018.06.030
doi: 10.1016/j.appet.2018.06.030
pubmed: 29958864
pmcid: 6778476
Bacaltchuk J, Hay P, Mari JJ (2000) Antidepressants versus placebo for the treatment of bulimia nervosa: a systematic review. Aust NZ J Psychiatry 34:310–317. https://doi.org/10.1080/j.1440-1614.2000.00709.x
doi: 10.1080/j.1440-1614.2000.00709.x
Bacaltchuk J, Hay PP (2003) Antidepressants versus placebo for people with bulimia nervosa. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003391
doi: 10.1002/14651858.CD003391
pubmed: 14583998
pmcid: 6991155
Akingbala F, Dhanani N, Sherwood Brown E (2006) Impulsivity in patients with bipolar disorder and cocaine or amphetamine dependence given lamotrigine. J Dual Diagn 2:73–83. https://doi.org/10.1300/J374v02n03_07
doi: 10.1300/J374v02n03_07
Tritt K, Nickel C, Lahmann C, Leiberich PK, Rother WK, Loew TH, Nickel MK (2005) Lamotrigine treatment of aggression in female borderline-patients: a randomized, double-blind, placebo-controlled study. J Psychopharmacol (Oxf) 19:287–291. https://doi.org/10.1177/0269881105051540
doi: 10.1177/0269881105051540
Li X, Large CH, Ricci R, Taylor JJ, Nahas Z, Bohning DE, Morgan P, George MS (2011) Using interleaved transcranial magnetic stimulation/functional magnetic resonance imaging (fMRI) and dynamic causal modeling to understand the discrete circuit specific changes of medications: lamotrigine and valproic acid changes in motor or prefrontal effective connectivity. Psychiatry Res Neuroimaging 194:141–148. https://doi.org/10.1016/j.pscychresns.2011.04.012
doi: 10.1016/j.pscychresns.2011.04.012
Jogia J, Haldane M, Cobb A, Kumari V, Frangou S (2008) Pilot investigation of the changes in cortical activation during facial affect recognition with lamotrigine monotherapy in bipolar disorder. Br J Psychiatry 192:197–201. https://doi.org/10.1192/bjp.bp.107.037960
doi: 10.1192/bjp.bp.107.037960
pubmed: 18310580